Vir Biotechnology Business Summary

Vir Biotechnology, Inc. (VIR) is a commercial-stage immunology company that generates revenue primarily through collaboration agreements, licensing fees, and government or philanthropic grants. Its business model is centered on high-value clinical development, transitioning from pandemic-era product sales to a long-term pipeline focused on two primary segments: infectious diseases and oncology. The company leverages its next-generation antibody platform and the PRO-XTEN protease-releasable masking technology to develop therapies for chronic hepatitis delta (CHD), HIV, and various solid tumors. As of early 2026, Vir is aggressively advancing its Phase 3 ECLIPSE registrational program for CHD and Phase 1 oncology candidates like VIR-5500. Within the biotechnology landscape, Vir competes directly with firms such as ADMA Biologics, Arcellx, and Kiniksa Pharmaceuticals, positioning itself as a specialized leader in immune-programming for complex viral and malignant pathologies. The company was founded by a team of industry veterans, including Klaus Frueh and founding CEO George Scangos, who previously led Biogen and Exelixis. The current leadership is headed by Chief Executive Officer Marianne De Backer, Ph.D., who joined in 2023 following a distinguished tenure as EVP at Bayer. The technical executive suite includes Aine Hanly, Ph.D., as Executive Vice President and Chief Technology Officer (formerly of Amgen and Pfizer), and Jason O’Byrne as EVP and Chief Financial Officer. Vir is supported by a high-pedigree board of directors, including Chairman Vicki Sato and former U.S. Secretary of Homeland Security Janet Napolitano. Notable institutional investors and partners include SoftBank Vision Fund, ARCH Venture Partners, the Bill & Melinda Gates Foundation, and the Alaska Permanent Fund, reflecting a robust capital base and strategic alignment with global health and venture leaders.